<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27748638</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1941-2703</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>30</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of aerosol medicine and pulmonary drug delivery</Title>
          <ISOAbbreviation>J Aerosol Med Pulm Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The History of Therapeutic Aerosols: A Chronological Review.</ArticleTitle>
        <Pagination>
          <StartPage>20</StartPage>
          <EndPage>41</EndPage>
          <MedlinePgn>20-41</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1089/jamp.2016.1297</ELocationID>
        <Abstract>
          <AbstractText>In 1956, Riker Laboratories, Inc., (now 3 M Drug Delivery Systems) introduced the first pressurized metered dose inhaler (MDI). In many respects, the introduction of the MDI marked the beginning of the modern pharmaceutical aerosol industry. The MDI was the first truly portable and convenient inhaler that effectively delivered drug to the lung and quickly gained widespread acceptance. Since 1956, the pharmaceutical aerosol industry has experienced dramatic growth. The signing of the Montreal Protocol in 1987 led to a surge in innovation that resulted in the diversification of inhaler technologies with significantly enhanced delivery efficiency, including modern MDIs, dry powder inhalers, and nebulizer systems. The innovative inhalers and drugs discovered by the pharmaceutical aerosol industry, particularly since 1956, have improved the quality of life of literally hundreds of millions of people. Yet, the delivery of therapeutic aerosols has a surprisingly rich history dating back more than 3500 years to ancient Egypt. The delivery of atropine and related compounds has been a crucial inhalation therapy throughout this period and the delivery of associated structural analogs remains an important therapy today. Over the centuries, discoveries from many cultures have advanced the delivery of therapeutic aerosols. For thousands of years, therapeutic aerosols were prepared by the patient or a physician with direct oversight of the patient using custom-made delivery systems. However, starting with the Industrial Revolution, advancements in manufacturing resulted in the bulk production of therapeutic aerosol delivery systems produced by people completely disconnected from contact with the patient. This trend continued and accelerated in the 20th century with the mass commercialization of modern pharmaceutical inhaler products. In this article, we will provide a summary of therapeutic aerosol delivery from ancient times to the present along with a look to the future. We hope that you will find this chronological summary intriguing and informative.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stein</LastName>
            <ForeName>Stephen W</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>1 3 M Drug Delivery Systems , St. Paul, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thiel</LastName>
            <ForeName>Charles G</ForeName>
            <Initials>CG</Initials>
            <AffiliationInfo>
              <Affiliation>2 Retired, Tucson, Arizona.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016456">Historical Article</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Aerosol Med Pulm Drug Deliv</MedlineTA>
        <NlmUniqueID>101475057</NlmUniqueID>
        <ISSNLinking>1941-2711</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000336" MajorTopicYN="N">Aerosols</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058995" MajorTopicYN="N">Dry Powder Inhalers</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049690" MajorTopicYN="N">History, Ancient</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036501" MajorTopicYN="N">Metered Dose Inhalers</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="N">Nebulizers and Vaporizers</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">atropine</Keyword>
        <Keyword MajorTopicYN="N">dry powder inhaler</Keyword>
        <Keyword MajorTopicYN="N">inhaler</Keyword>
        <Keyword MajorTopicYN="N">metered dose inhaler</Keyword>
        <Keyword MajorTopicYN="N">nebulizer</Keyword>
        <Keyword MajorTopicYN="N">therapeutic aerosol</Keyword>
      </KeywordList>
      <CoiStatement>Author Disclosure Statement No competing financial interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27748638</ArticleId>
        <ArticleId IdType="pmc">PMC5278812</ArticleId>
        <ArticleId IdType="doi">10.1089/jamp.2016.1297</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Breasted JH: The Edwin Smith Surgical Papyrus. University of Chicago Press, Chicago, IL; 1930</Citation>
        </Reference>
        <Reference>
          <Citation>Ebbell B: The Papyrus Ebers: The Greatest Egyptian Medical Document (translation to English). Levin and Munksgaard, Copenhagen; p. 67, 1937</Citation>
        </Reference>
        <Reference>
          <Citation>Sanders M: Inhalation therapy: An historical review. Prim Care Respir J. 2007;16:71–81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6634187</ArticleId>
            <ArticleId IdType="pubmed">17356785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alizadeh A, Moshiri M, Alizadeh J, and Balali-Mood M: Black henbane and its toxicity—A descriptive review. Avicenna J Phytomed. 2014;4:297–311</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4224707</ArticleId>
            <ArticleId IdType="pubmed">25386392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kritikos PG, and Papadaki SP: The early history of the poppy and opium. Bull Narcotics. 1967;19:17–38</Citation>
        </Reference>
        <Reference>
          <Citation>Heydari M, Hashempur MH, and Zargaran A: Medicinal aspects of opium as described in Avicenna's Canon of Medicine. Acta Med Hist Adriat. 2013;11:101–112</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23883087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandevia B: Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J. 1975;51 (Suppl. 7):13–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">785420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan R: Historical aspects of bronchial asthma. Indian J Chest Dis. 1964;6:165–169</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson PJ: History of aerosol therapy: Liquid nebulization to MDIs to DPIs. Respir Care. 2005;50:1139–1150</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16122398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shehata M: History of inhalation therapy. Internet J Health. 2008;9:1–9</Citation>
        </Reference>
        <Reference>
          <Citation>Solis-Cohen J: Inhalation in the Treatment of Disease, Its Therapeutics and Practice: A Treatise On the Inhalation of Gases, Vapors, Nebulized Fluids, and Powders. Lindsay &amp; Blakiston, Philadelphia; pp. 19–21,193–340, 1867</Citation>
        </Reference>
        <Reference>
          <Citation>Tissier PLA: Pneumotherapy, including aerotherapy and inhalation methods and therapy, volume 10 In: Cohen SS. (ed). A System of Physiologic Therapeutics. P. Blakiston's Son &amp; Co., Philadelphia, PA:  pp. 440–451, 1903</Citation>
        </Reference>
        <Reference>
          <Citation>Brenner BE: Where have we been? The history of acute asthma, In: Brenner BE. (ed). Emergency Asthma. Marcel Dekker, Inc., New York; pp. 1–32, 1999</Citation>
        </Reference>
        <Reference>
          <Citation>Bostock J, and Riley HT: The Natural History of Pliny, Volume V (translation to English). Henry G. Bohn, London; 1856</Citation>
        </Reference>
        <Reference>
          <Citation>Lee MR: The history of Ephedra (ma-huang). J R Coll Phys Edinburgh. 2011;41:78–84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21365072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scudder JM: Eclectic Manual No. 2 on the Use of Medicated Inhalations in the Treatment of Diseases of the Respiratory Organs. John M Scudder's Sons, Cincinnati, OH; p. 21, 1895</Citation>
        </Reference>
        <Reference>
          <Citation>Mudge J: A Radical and Expeditious Cure for a Recent Catarrhous Cough, 2nd Edition. E. Allen, London; pp. 131–147, 1778</Citation>
        </Reference>
        <Reference>
          <Citation>Sanders M: 2016, Lynch inhaler. www.inhalatorium.com/wpcproduct/lynch-inhaler/ (accessed September8, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Nikander K, and Sanders M: The early evolution of nebulizers. Medicamundi. 2010;54:47–53</Citation>
        </Reference>
        <Reference>
          <Citation>Long CW: An account of the first use of sulphuric ether by inhalation as an anaesthetic in surgical operations. South Med Surg J. 1849;5:705–713</Citation>
        </Reference>
        <Reference>
          <Citation>Steward DJ: The early history of anaesthesia in Canada: The introduction of ether to upper Canada. 1847, Can Anaesthet Soc J. 1977;24:153–161</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">321101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sneader W: Systemic medicine. In: Sneader W. (ed). Drug Discovery—A History. John Wiley and Sons Ltd., Chichester, West Sussex, England; pp. 74–87, 2005</Citation>
        </Reference>
        <Reference>
          <Citation>Warren I: The Household Physician; for the Use of Families, Planters, Seamen, and Travellers. Being a Brief Description, in Plain Language, of all the Diseases of Men, Women, and Children, with the Newest and Most Approved Methods of Curing Them. Higgins, Bradley, and Dayton; Boston, MA:  pp. 189–224, 1859</Citation>
        </Reference>
        <Reference>
          <Citation>Bleyer JM: A new method of laryngeal and bronchial medication by means of a spray and tube during the act of deep inspiration: Read in the Section of Laryngology and Otology at the Forty-first Annual Meeting of the American Medical Association, Nashville, Tenn., May, 1890. J Am Med Assoc. 1890;XV:634–636</Citation>
        </Reference>
        <Reference>
          <Citation>Wyeth J: An Epitome of Therapeutics with Special Reference to the Laboratory Products of John Wyeth and Brother. John Wyeth &amp; Brother, Inc., Philadelphia, PA; pp. 251–252; 1901</Citation>
        </Reference>
        <Reference>
          <Citation>Helbing H, and Pertsch G: Collodion mixture. U.S. patent 628,463; July
11, 1899</Citation>
        </Reference>
        <Reference>
          <Citation>Clark AR: Medical aerosol inhalers: Past, present, and future. Aerosol Sci Technol. 1995;22:374–391</Citation>
        </Reference>
        <Reference>
          <Citation>Rau JL: The inhalation of drugs: Advantages and problems. Respir Care. 2005;50:367–382</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15737247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson PJ: Delivery options and devices for aerosolized therapeutics. Chest. 2001;120:89S–93S</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11555561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brennan P, Crispo A, Zaridze D, Szeszenia-Dabrowksa N, Rudnai P, Lissowska J, Fabiánová E, Mates D, Bencko V, Foretova L, Janout V, Fletcher T, and Boffetta P: High cumulative risk of lung cancer death among smokers and nonsmokers in central and eastern Europe. Am J Epidemiol. 2006;164:1233–1241</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17032696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elliott HL, and Reid JL: The clinical pharmacology of a herbal asthma cigarette. Br J Clin Pharmacol. 1980;10:487–490</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1430151</ArticleId>
            <ArticleId IdType="pubmed">7437260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IMS Health (MIDAS January 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Chen BT, Namenyi J, Yeh HC, Mauderly JL, and Cuddihy RG: Physical characterization of cigarette smoke aerosol generated from a Walton smoke machine. Aerosol Sci Technol. 1990;12:364–375</Citation>
        </Reference>
        <Reference>
          <Citation>Beatson G: Practical papers on the materials of the antiseptic method of treatment, Vol. III, on spray producers. In: Coat J. (ed). Glasgow Medical Journal, edited for the West of Scotland Medical Association, Vol. XIV. Alex and Macdougall, Glasgow; pp. 461–484, 1880</Citation>
        </Reference>
        <Reference>
          <Citation>Abramson HA: Principles and practice of aerosol therapy of the lungs and bronchi. Ann Allergy. 1946;4:440–456</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20279661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scudder JM: On the Use of Medicated Inhalations, in the Treatment of Diseases of the Respiratory Organs. Moore, Wilstach &amp; Baldwin, Printers, Cincinnati, OH; pp. 27–37, 1867</Citation>
        </Reference>
        <Reference>
          <Citation>Warren I: Inhaler. U.S. patent 8,813; March
16, 1852</Citation>
        </Reference>
        <Reference>
          <Citation>Jackson WA: The carbolic smoke ball. Pharm Historian. 1984;14:9–10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11630964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarfield AM: The strange case of Miss E.C. Carlill versus the Carbolic Smoke Ball Company. Ann Long Term Care. 2005;13:46–47</Citation>
        </Reference>
        <Reference>
          <Citation>Newton A: Inhaling apparatus. U.K. patent 1161; May
7, 1864</Citation>
        </Reference>
        <Reference>
          <Citation>Fields MR: Inhalator, U.S. patent 2,470,296; May
17, 1949</Citation>
        </Reference>
        <Reference>
          <Citation>Krasno LR, and Rhoads PS: The inhalation of penicillin dust; its proper role in the management of respiratory infections. Am Practitioner. 1949;3:649–653</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18152211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solis-Cohen S: The use of adrenal substance in the treatment of acute asthma. JAMA. 1900;34:1164–1166</Citation>
        </Reference>
        <Reference>
          <Citation>O'Callaghan C, Nerbrink O, and Vidgren MT: The history of inhaled drug therapy, In: Bisgaard H, O'Callaghan C, and Smaldone GC. (eds). Drug Delivery to the Lung. Informa Healthcare, New York; pp. 1–20, 2007</Citation>
        </Reference>
        <Reference>
          <Citation>Gelfand ML: Administration of cortisone by the aerosol method in the treatment of bronchial asthma. N Engl J Med. 1951;245:293–294</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14863574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiel CG: From Susie's question to CFC-free: An inventor's perspective on forty years of MDI development and regulation. Respir Drug Deliv. 1996;1:115–123</Citation>
        </Reference>
        <Reference>
          <Citation>Freedman T: Medihaler® therapy for bronchial asthma. Postgrad Med. 1956;20:667–673</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13379123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin W, Lowell FC, Michelson AL, and Schiller IW: Aerosolized steroids in bronchial asthma. J Allergy. 1958;29:214–221</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13538614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman S: Additional technology for metered dose inhalers. In: Newman S. (ed). Respiratory Drug Delivery: Essential Theory &amp; Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 217–256, 2009</Citation>
        </Reference>
        <Reference>
          <Citation>Bloomfield P, Crompton GK, and Winsey NJP: A tube spacer to improve inhalation of drugs from pressurized aerosols. Br Med J. 1979;2:1479</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1597156</ArticleId>
            <ArticleId IdType="pubmed">526820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikander K, Nicholls C, Denyer J, and Pritchard J: The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv. 2014;27(S1):S4–S23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25054481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolovich M, Ruffin R, Corr D, and Newhouse MT: Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest. 1983;84:36–41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6861546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman SP, Moren F, Pavia D, Little F, and Clarke SW: Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124:317–320</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7283266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lands AM, Arnold A, McAuliff JP, Luduena FP, and Brown TG: Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967;214:597–598</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6036174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryan J: Ventolin remains a breath of fresh air for asthma sufferers, after 40 years. Pharm J. 2007;279:404–405</Citation>
        </Reference>
        <Reference>
          <Citation>Bell JH, Hartley PS, and Cox JSG: Dry powder aerosol I: A new powder inhalation device. J Pharm Sci. 1971;60:1559–1564</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5129375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nerbrink O, Dahlbäck M, and Hansson HC: Why do medical nebulizers differ in their output and particle size characteristics?
J Aerosol Med. 1994;7:259–276</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10150483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cipolla DC, Clark AR, Chan I, Gonda I, and Shire SJ: Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. S.T.P. Pharma Sci. 1994;4:50–62</Citation>
        </Reference>
        <Reference>
          <Citation>O'Callaghan C, and Barry PW: The science of nebulized drug delivery. Thorax. 1997;52(S2):S31–S44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1765865</ArticleId>
            <ArticleId IdType="pubmed">9155849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang RJ: Ultrasonic atomization of liquids. J Acoust Soc Am. 1962;34:6–9</Citation>
        </Reference>
        <Reference>
          <Citation>Leach C: The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50:1201–1206</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16122403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Montreal Protocol on substances that deplete the ozone layer, Final Act (Nairobi: UNEP 1987). Federal Register. 1994; 59 FR 56276–56298</Citation>
        </Reference>
        <Reference>
          <Citation>Molina M, and Rowland F: Stratospheric sink for chlorofluoromethanes: Chlorine atom-catalysed destruction of ozone. Nature. 1974;249:810–812</Citation>
        </Reference>
        <Reference>
          <Citation>Atkins PJ: Transition to HFA MDIs: How did we get here and where are we going?
Respir Drug Deliv. 2006;1:83–90</Citation>
        </Reference>
        <Reference>
          <Citation>Rogueda P, Lallement A, Traini D, Iliev I, and Young PM: Twenty years of HFA pMDI patents: Facts and perspectives. J Pharm Pharmacol. 2012;64:1209–1216</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22881434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purewal TS, and Greenleaf DJ: Medicinal aerosol formulations. GB8828477; 1989</Citation>
        </Reference>
        <Reference>
          <Citation>Heiskel E, and Schmieder W: Druckgaspackung und treibmittel für aerosole. DE3905726A1; 1990</Citation>
        </Reference>
        <Reference>
          <Citation>Weil HH, and Daab O: Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen. DE4003272A1; 1990</Citation>
        </Reference>
        <Reference>
          <Citation>Stein SW, Sheth P, and Myrdal PB: Advances in metered dose inhaler technology: Hardware development. AAPS PharmSciTech. 2014;15:326–328</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3969498</ArticleId>
            <ArticleId IdType="pubmed">24357110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross DL, and Gabrio BJ: Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med. 1999;12:151–160</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10623331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vervaet C, and Byron PR: Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 1999;186:13–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10469920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Z, Thatcher ML, Lundberg JK, Ogawa MK, Jacoby CB, Battiste JL, and Ledoux KA: Forced degradation studies of corticosteroids with an alumina-steroid-ethanol model for predicting chemical stability and degradation products of pressurized metered-dose inhaler formulations. J Pharm Sci. 2012;101:2109–2122</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22410760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrewsbury SB, Armer TA, Newman SP, and Pitcairn G: Breath synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharm. 2008;356:137–143</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18289809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrio BJ, and Velasquez DJ: Inventors; 3 M Innovative Properties Company, assignee. Slow spray metered dose inhaler. U.S. patent 6,615,826; September 9, 2003</Citation>
        </Reference>
        <Reference>
          <Citation>Leach CL, Davidson PJ, Hasselquist BE, and Boudreau RH: Lung deposition of HFA-134a beclomethasone is greater than that of chlorofluorcarbon fluticasone and chlorofluorcarbon beclomethasone: A cross-over study in health volunteers. Chest. 2002;122:510–516</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12171824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, and Colice GL: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215–1222</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10589004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postma DS, and van den Berge M: Small airway dysfunction in asthma and COPD: Consequences for therapy and the future. Respir Drug Deliv Europe. 2013;1:1–12</Citation>
        </Reference>
        <Reference>
          <Citation>van den Berge M, ten Hacken NHT, van der Wiel E, and Postma DS: Treatment of the bronchial tree from beginning to end: Targeting small airway inflammation in asthma. Allergy. 2013;68:16–26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23210509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration: Guidance for industry: Integration of dose-counting mechanisms into MDI drug products. 2003.  (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071731.pdf) (accessed September8, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Woodcock A: Responsible inhaler development in article 5 countries: Navigating the scientific, regulatory, political and commercial challenges. Respir Drug Deliv. 2010;1:121–129</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration: Consumer update: Primatine Mist with chlorofluorocarbons no longer available after December
31, 2011.  (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm247196.htm) (accessed September8, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Chrystyn H: The Diskus™: A review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61:1022–1036</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1974824</ArticleId>
            <ArticleId IdType="pubmed">17504364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins PJ: Dry powder inhalers: An overview. Respir Care. 2005;50:1304–1312</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16185366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frijlink HW, and De Boer AH: Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1:67–86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16296721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill M: Characteristics of an active multiple dose dry powder inhaler. Respir Drug Deliv. 1994;IV:109–116</Citation>
        </Reference>
        <Reference>
          <Citation>Newman S, and Peart J: Dry powder inhalers. In: Newman S. (ed). Respiratory Drug Delivery: Essential Theory &amp; Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 257–307, 2009</Citation>
        </Reference>
        <Reference>
          <Citation>Staniforth JN: Pre-formulation aspects of dry powder aerosols. Respir Drug Deliv. 1996;V:65–73</Citation>
        </Reference>
        <Reference>
          <Citation>Zeng XM, Tee S-K, Martin GP, and Marriott C: Improving the delivery efficiency of dry powder inhalers (DPIs) by adding fine carrier particles to powder formulations. Thorax. 1996;51(S3):A74</Citation>
        </Reference>
        <Reference>
          <Citation>Zeng XM, Martin GP, Tee S-K, and Marriott C: The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm. 1998;176:99–110</Citation>
        </Reference>
        <Reference>
          <Citation>Islam N, Stewart PJ, Larson I, and Hartley P: Lactose surface modification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose interactive mixtures?
Pharm Res. 2004;21:492–499</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones MD, and Price R: The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res. 2006;23:1665–1674</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16845584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staniforth JN: Nasal and pulmonary powder opportunities: New drugs and formulations for rapid systemic onset. Respir Drug Deliv. 2006;1:249–256</Citation>
        </Reference>
        <Reference>
          <Citation>Mueller-Walz R, Fueg LM, Niederlaender C, Pieles U, and Wirth A: Ternary additives: Manipulation and control with magnesium stearate. Respir Drug Deliv. 2006;1:343–350</Citation>
        </Reference>
        <Reference>
          <Citation>Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebrai A, Eskew ML, Mintzes J, Deaver D, Lotan N, and Langer R: Large porous particles for pulmonary drug delivery. Science. 1997;276:1868–1872</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9188534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swenson C, Laseman J, and Busse W: Combination of salmeterol (SAL) and fluticasone (FP) works synergistically to inhibit airway inflammation post allergen challenge. J Allergy Clin Immunol. 2003;111:S126</Citation>
        </Reference>
        <Reference>
          <Citation>Nelson HS, Chapman KR, Pyke SD, Johnson M, and Pritchard JN: Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12847476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman S: Nebulizers. In: Newman S. (ed). Respiratory Drug Delivery: Essential Theory &amp; Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 135–176, 2009</Citation>
        </Reference>
        <Reference>
          <Citation>Knoch M, and Wunderlich E: In-vitro assessment of a new efficient nebulizer system for continuous operation. Respir Drug Deliv. 1994;IV:265–271</Citation>
        </Reference>
        <Reference>
          <Citation>Newman S: Emerging inhaler technologies. In: Newman S. (ed). Respiratory Drug Delivery: Essential Theory &amp; Practice. Respiratory Drug Delivery Online, Richmond, VA; pp. 309–336, 2009</Citation>
        </Reference>
        <Reference>
          <Citation>Dalby RN, Spallek M, and Voshaar T: A review of the development of the Respimat soft mist inhaler. Int J Pharm. 2004;283:1–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15363496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gansslen M: Uber inhalation von insulin. Klin Wochenschr. 1925;4:71</Citation>
        </Reference>
        <Reference>
          <Citation>Niven RW: Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151–231</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9501969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolff RK: Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11:197–219</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10346664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patton JS, and Platz RM: Aerosol insulin—A brief review. Respir Drug Deliv. 1994;IV:65–74</Citation>
        </Reference>
        <Reference>
          <Citation>Heinemann L: The failure of Exubera: Are we beating a dead horse?
J Diabetes Sci Technol. 2008;2:518–529</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2769732</ArticleId>
            <ArticleId IdType="pubmed">19885220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavaiola TS, and Edelman S: Inhaled insulin: A breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36:1275–1289</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25044021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaMattina J: Challenges in commercializing inhaled insulin. Available at: www.forbes.com (Last accessed August23, 2013)</Citation>
        </Reference>
        <Reference>
          <Citation>Berenson A: Weak sales prompt Pfizer to cancel diabetes drug. Available at: www.nytimes.com (Last accessed October19, 2007)</Citation>
        </Reference>
        <Reference>
          <Citation>Gonda I: The ascent of pulmonary drug delivery. J Pharm Sci. 2000;89:940–945</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10861595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klinger-Strobel M, Lautenschläger C, Fischer D, Mainz JG, Bruns T, Tuchscherr L, Pletz MW, and Makarewicz O: Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis—Where do we stand?
Expert Opin Drug Deliv. 2015;12:1351–1374</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25642831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry PJ, and Jones AM: New and emerging treatments for cystic fibrosis. Drugs. 2015;75:1165–1175</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26091951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carnovale V, Iacotucci P, Cellurale M, d'Ippolito M, Buonauriou S, Celardo A, and Ferrara N: Inhalation therapy in cystic fibrosis. ACTA Biomed. 2014;85(S4):7–9</Citation>
        </Reference>
        <Reference>
          <Citation>Cyranoski D: Threat of pandemic brings flu drug back to life. Nat Med. 2005;11:909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16145557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, and Connor EM: Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685–696</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17301299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, and Sepulveda-Amor J: Aerosolized measles and measles-rubella vaccine induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Org. 2002;80:806–812</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2567652</ArticleId>
            <ArticleId IdType="pubmed">12471401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarkhedkar S, Kulkarni PS, Winston S, Sievers R, Dhere RM, Gunale B, Powell K, Rota PA, and Papania M: Safety and immunogenicity of dry powder measles vaccine adminstered by inhalation: A randomized controlled Phase I clinical trial. Vaccine. 2014;32:6791–6797</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25446830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubin BK: Air and soul: The science and application of aerosol therapy. Respir Care. 2010;55:911–921</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20587104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidson L: Vaping takes off as e-cigarette sales break through $6bn. The Telegraph 2015. Available at: www.telegraph.co.uk/finance/newsbysector/retailandconsumer/11692435/Vaping-takes-off-as-e-cigarette-sales-break-through-6bn.html (Last accessed June23, 2015)</Citation>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration: Deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco products. Available at: www.federalregister.gov/articles/2016/05/10/2016-10685/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the (Last accessed May10, 2016)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27192730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Medicare and Medicaid Services: National Health Expenditures Projections 2011–2021. Available at: www.cms.gov/Research-Statistics-data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/Proj2011PDF.pdf (Last accessed January22, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Karst KR: Jumping legal hurdles with the U.S. FDA: The generic inhaler challenge. Respir Drug Deliv Asia. 2014;1:151–158</Citation>
        </Reference>
        <Reference>
          <Citation>Hall JR, and Denyer MD: Contrasting regulatory equivalence demands between the EU and the US: History, law, markets and future needs. Respir Drug Deliv Eur. 2007;1:109–118</Citation>
        </Reference>
        <Reference>
          <Citation>Byron PR: Can we move toward harmonized requirements for bioequivalence of inhalers?
Respir Drug Deliv Eur. 2007;1:151–158</Citation>
        </Reference>
        <Reference>
          <Citation>Fuglsang A, Leach CL, Mayers I, and Chowdhury BA: Therapeutic equivalence of inhaled corticosteroids—Workshop on regional differences in regulatory requirements. Respir Drug Deliv. 2008;1:133–150</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration: Draft guidance on albuterol sulfate. 2013.  (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm346985.pdf) (accessed September8, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration: Draft guidance on fluticasone propionate; salmeterol xinafoate. 2013.  (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm367643.pdf) (accessed September8, 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Singh S, Kanbar-Agha F, and Sharafkhaneh A: Novel aerosol delivery devices. Semin Respir Crit Care Med. 2015;36:543–551</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26238640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van sickle D, Maenner MJ, Barrett MA, and Marcus JE: Monitoring and improving compliance and asthma control: Mapping inhaler use for feedback to patients, physicians and payers. Respir Drug Deliv Eur. 2013;1:119–130</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
